Curanex制药公司正稳步推进其候选药物Phyto-N的开发进程。公司计划在2026年第四季度向美国食品药品监督管理局（FDA）提交针对溃疡性结肠炎的研究性新药申请。这一关键步骤标志着该药物向临床试验阶段迈出了重要的一步。
Curanex制药公司正稳步推进其候选药物Phyto-N的开发进程。公司计划在2026年第四季度向美国食品药品监督管理局（FDA）提交针对溃疡性结肠炎的研究性新药申请。这一关键步骤标志着该药物向临床试验阶段迈出了重要的一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.